Qing Song (6931) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 青松健康

Qing Song (6931) reported revenue of NT$114.4 million for Oct 2026, +17.0% year on year and +3.1% from the previous month. Revenue for Jan–Oct 2026 was NT$1.08 billion (+17.1% year on year).

Revenue for Oct 2026 was a record high (previous high: Jul 2026, NT$112.4 million). →

Year-on-year revenue growth: 25+ months in a row. →

In Oct 2026, it ranked No. 66 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$82.3 million24/10Nov 2024 NT$85.3 millionDec 2024 NT$88.8 millionJan 2025 NT$83.9 millionFeb 2025 NT$84.3 million25/02Mar 2025 NT$89.8 millionApr 2025 NT$93.8 millionMay 2025 NT$95.7 millionJun 2025 NT$92.9 million25/06Jul 2025 NT$90.3 millionAug 2025 NT$94.2 millionSep 2025 NT$100 millionOct 2025 NT$97.8 million25/10Nov 2025 NT$96.9 millionDec 2025 NT$102.2 millionJan 2026 NT$105.2 millionFeb 2026 NT$89.6 million26/02Mar 2026 NT$109.8 millionApr 2026 NT$105.7 millionMay 2026 NT$109.6 millionJun 2026 NT$110.4 million26/06Jul 2026 NT$112.4 millionAug 2026 NT$112.1 millionSep 2026 NT$110.9 millionOct 2026 NT$114.4 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$114.4 million+17.0%+3.1%
Sep 2026NT$110.9 million+10.9%-1.0%
Aug 2026NT$112.1 million+19.0%-0.3%
Jul 2026NT$112.4 million+24.5%+1.8%
Jun 2026NT$110.4 million+18.8%+0.8%
May 2026NT$109.6 million+14.6%+3.6%
Apr 2026NT$105.7 million+12.7%-3.7%
Mar 2026NT$109.8 million+22.2%+22.5%
Feb 2026NT$89.6 million+6.4%-14.8%
Jan 2026NT$105.2 million+25.3%+3.0%
Dec 2025NT$102.2 million+15.0%+5.5%
Nov 2025NT$96.9 million+13.6%-0.9%
Oct 2025NT$97.8 million+18.8%-2.3%
Sep 2025NT$100 million+16.7%+6.2%
Aug 2025NT$94.2 million+9.0%+4.3%
Jul 2025NT$90.3 million+9.4%-2.8%
Jun 2025NT$92.9 million+13.6%-2.9%
May 2025NT$95.7 million+14.3%+2.0%
Apr 2025NT$93.8 million+18.0%+4.4%
Mar 2025NT$89.8 million+13.9%+6.6%
Feb 2025NT$84.3 million+19.4%+0.4%
Jan 2025NT$83.9 million+8.8%-5.5%
Dec 2024NT$88.8 million+14.1%+4.1%
Nov 2024NT$85.3 million+10.6%+3.6%
Oct 2024NT$82.3 million+3.4%-4.0%

Jan–Oct 2026 cumulative: NT$1.08 billion (+17.1% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Qing Song vs PEC / Qing Song vs Lotus Pharm / Qing Song vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16